On March 11, 2026, Lineage Cell Therapeutics, Inc. filed a prospectus with the SEC. The filing includes Exhibit 5.1, the opinion of Sheppard, Mullin, Richter & Hampton LLP, and Exhibit 23.1, their consent.
Key takeaways
Filed prospectus with SEC on 2026-03-11
Exhibit 5.1: Opinion of Sheppard, Mullin, Richter & Hampton LLP
Exhibit 23.1: Consent of Sheppard, Mullin, Richter & Hampton LLP